Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipidem + Gemcitabine in Unresectable Pancreatic Adenocarcinoma
NCT01019382Phase 2Completed
- Sponsor
- University Hospitals of Leicester NHS Trust
- Start
- Oct 2009
- Primary completion
- Jun 2014
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Lipidem in pancreatic adenocarcinoma (PDAC), sponsored by University Hospitals of Leicester NHS Trust. Primary endpoint: Objective Response Rate at 2 months. Started Oct 2009; status: completed.
02
Drugs
Lipidem
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01019382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01019382.